“Croda’s biggest investments are in the life sciences business, as we are purposefully moving from consumer health to patient health, and thus to supplying specialty chemicals, excipients, vaccines, and, with our Avanti acquisitions, making a presence in lipid nanoparticles. We will also scale our bio-technology solutions to meet our sustainability ambitions.”
Babu Alagappan, Managing Director, Croda Singapore